ErbB2 pathways in heart and neural diseases

Trends in Cardiovascular Medicine

Volumn 13, Issue 2, 2003, Pages 80-86

  Garratt, Alistair N ^a   Özcelik, Cemil ^a   Birchmeier, Carmen ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

BREAST CANCER; CANCER GENETICS; CARDIOMYOPATHY; EMBRYO DEVELOPMENT; GENE FUNCTION; GENE MUTATION; HEART DEVELOPMENT; HEART DILATATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; ONCOGENE NEU; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN FAMILY; PROTO ONCOGENE; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

EID: 0037312369     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(02)00231-1     Document Type: Review

References (59)

1. Asakura M., Kitakaze M., Takashima S.et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF. metalloproteinase inhibitors as a new therapy Nat Med. 8:2002;35-40.
2. Bange J., Zwick E., Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 7:2001;548-552.
3. Behr T.M., Behe M., Wormann B. Trastuzumab and breast cancer. N Engl J Med. 345:2001;995-996.
4. Bolino A., Muglia M., Conforti F.L.et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet. 25:2000;17-19.
5. Britsch S., Li L., Kirchhoff S.et al. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 12:1998;1825-1836.
6. Britsch S., Goerich D.E., Riethmacher D.et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 15:2001;66-78.
7. Burden S., Yarden Y. Neuregulins and their receptors. a versatile signaling module in organogenesis and oncogenesis Neuron. 18:1997;847-855.
8. Carrasco Guerra H.A., Palacios-Pru E., Dagert de Scorza C.et al. Clinical, histochemical, and ultrastructural correlation in septal endomyocardial biopsies from chronic chagasic patients. detection of early myocardial damage Am Heart J. 113:1987;716-724.
9. Chien K.R. Myocyte survival pathways and cardiomyopathy. implications for trastuzumab cardiotoxicity Semin Oncol. 27:2000;9-14.
10. Crackower M.A., Oudit G.Y., Kozieradzki I.et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:2002;737-749.
11. Crone S.A., Zhao Y.Y., Fan L.et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 8:2002;459-465.
12. Ehler E., Horowits R., Zuppinger C.et al. Alterations at the intercalated disk associated with the absence of muscle LIM protein. J Cell Biol. 153:2001;763-772.
13. Erickson S.L., O'Shea K.S., Ghaboosi N.et al. ErbB3 is required for normal cerebellar and cardiac development. a comparison with ErbB2-and heregulin-deficient mice Development. 124:1997;4999-5011.
14. 2 +/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation. J Biol Chem. 274:1999;16,168-16,173.
15. Ford B.D., Loeb J.A., Fischbach G.D. Neuregulin stimulates DNA synthesis in embryonic chick heart cells. Dev Biol. 214:1999;139-150.
16. Garratt A.N., Britsch S., Birchmeier C. Neuregulin, a factor with many functions in the life of a Schwann cell. Bioessays. 22:2000;987-996. a.
17. Garratt A.N., Voiculescu O., Topilko P.et al. A dual role of erbB2 in myelination and in expansion of the Schwann cell precursor pool. J Cell Biol. 148:2000;1035-1046. b.
18. Gassmann M., Casagranda F., Orioli D.et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 378:1995;390-394.
19. Hertig C.M., Kubalak S.W., Wang Y., Chien K.R. Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem. 274:1999;37,362-37,369.
20. Hilborn M.D., Vaillancourt R.R., Rane S.G. Growth factor receptor tyrosine kinases acutely regulate neuronal sodium channels through the src signaling pathway. J Neurosci. 18:1998;590-600.
21. Hirota H., Chen J., Betz U.A.et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 97:1999;189-198.
22. Hynes N.E., Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1198:1994;165-184.
23. Kalaydjieva L., Gresham D., Gooding R.et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet. 67:2000;47-58.
24. Kramer R., Bucay N., Kane D.J.et al. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci USA. 93:1996;4833-4838.
25. Lai K.M., Pawson T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev. 14:2000;1132-1145.
26. Le Douarin N.M. The Neural Crest. 1982;Cambridge University Press, Cambridge, MA.
27. Lee K.F., Simon H., Chen H.et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
28. Lemke G. Neuregulins in development. Mol Cell Neurosci. 7:1996;247-262.
29. Liu X., Hwang H., Cao L.et al. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci USA. 95:1998;13,024-13,029.
30. Meyer D., Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 378:1995;386-390.
31. Morris J.K., Lin W., Hauser C.et al. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron. 23:1999;273-283.
32. Nuyens D., Stengl M., Dugarmaa S.et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med. 7:2001;1021-1027.
33. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network. receptor heterodimerization in development and cancer EMBO J. 19:2000;3159-3167.
34. Özcelik C., Erdmann B., Pilz B.et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA. 99:2002;8880-8885.
35. Papadatos G.A., Wallerstein P.M., Head C.E.et al. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci USA. 99:2002;6210-6215.
36. Rajewsky K., Gu H., Kuhn R.et al. Conditional gene targeting. J Clin Invest. 98:1996;600-603.
37. Rentschler S., Zander J., Meyers K.et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci USA. 99:2002;10,464-10,469.
38. Riese D.J., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20:1998;41-48.
39. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V.et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:1997;725-730.
40. Sawyer D.B., Zuppinger C., Miller T.A.et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2. potential mechanism for trastuzumab-induced cardiotoxicity Circulation. 105:2002;1551-1554.
41. Schaper J., Froede R., Hein S.et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 83:1991;504-514.
42. Schneider J.W., Chang A.Y., Garratt A. Trastuzumab cardiotoxicity. Speculations regarding pathophysiology and targets for further study Semin Oncol. 29:2002;22-28.
43. Sedmera D., Pexieder T., Vuillemin M.et al. Developmental patterning of the myocardium. Anat Rec. 258:2000;319-337.
44. Seidman A., Hudis C., Pierri M.K.et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 20:2002;1215-1221.
45. Slamon D.J., Clark G.M., Wong S.G.et al. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
46. Slamon D.J., Leyland-Jones B., Shak S.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.
47. Strachan L., Murison J.G., Prestidge R.L.et al. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem. 276:2001;18,265-18,271.
48. Taber L.A., Zahalak G.I. Theoretical model for myocardial trabeculation. Dev Dyn. 220:2001;226-237.
49. Tzahar E., Pinkas-Kramarski R., Moyer J.D.et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16:1997;4938-4950.
50. Uray I.P., Connelly J.H., Thomazy V.et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant. 21:2002;771-782.
51. Warner L.E., Garcia C.A., Lupski J.R. Hereditary peripheral neuropathies. clinical forms, genetics, and molecular mechanisms Annu Rev Med. 50:1999;263-275.
52. Wischmeyer E., Doring F., Karschin A. Acute suppression of inwardly rectifying Kir2.1 channels by direct tyrosine kinase phosphorylation. J Biol Chem. 273:1998;34,063-34,068.
53. Woldeyesus M.T., Britsch S., Riethmacher D.et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. Genes Dev. 13:1999;2538-2548.
54. Wolpowitz D., Mason T.B., Dietrich P.et al. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron. 25:2000;79-91.
55. Wu J.Y., Yu H., Cohen I.S. Epidermal growth factor increases i(f) in rabbit SA node cells by activating a tyrosine kinase. Biochim Biophys Acta. 1463:2000;15-19.
56. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:2001;127-137.
57. Yussman M.G., Toyokawa T., Odley A.et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med. 8:2002;725-730.
58. 2+ /calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 277:2002;1261-1267.
59. Zhao Y.Y., Sawyer D.R., Baliga R.R.et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:1998;10,261-10,269.